...
首页> 外文期刊>AIDS >Postexposure prophylaxis, preexposure prophylaxis or universal test and treat: the strategic use of antiretroviral drugs to prevent HIV acquisition and transmission.
【24h】

Postexposure prophylaxis, preexposure prophylaxis or universal test and treat: the strategic use of antiretroviral drugs to prevent HIV acquisition and transmission.

机译:暴露后预防,暴露前预防或普遍测试和治疗:战略性使用抗逆转录病毒药物来预防HIV的获取和传播。

获取原文
获取原文并翻译 | 示例
           

摘要

This review considers the use of antiretroviral drugs specifically to prevent HIV transmission. Antiretroviral therapy (ART) can be implemented for the protection of uninfected individuals both before (preexposure prophylaxis) and after (postexposure prophylaxis) exposure to HIV infection. Preexposure prophylaxis may be used coitally dependently when individuals are intermittently exposed or by continuous daily dosing for those constantly exposed; postexposure prophylaxis is used in 28-day courses. Alternatively, ART can be used strategically to reduce the viral load and consequent infectiousness of an HIV-infected individual, thereby limiting the risk of onward viral transmission. A policy of universal HIV testing to enhance the identification of all HIV-positive individuals followed by immediate treatment of all HIV-positive individuals, irrespective of their CD4 cell counts (universal test and treat), has been postulated as a potential tool capable of reducing HIV incidence at a population level. This concept represents a paradigm shift in the use of ART, targeting infectious individuals for prevention rather than protecting uninfected exposed populations. This strategy could have the advantage of preventing transmission and reducing HIV incidence at a population level, as well as delivering universal access to therapy for all people living with HIV and AIDS, potentially eliminating mother-to-child HIV transmission and limiting concomitant diseases such as tuberculosis. This review critically examines the scientific basis of ART for HIV prevention, summarizing the risks and opportunities of the potential expansion of ART for prevention. Specifically, we consider the evidences for and against targeting HIV-uninfected individuals compared with enhanced HIV testing and treatment of HIV-infected individuals in terms of impact on viral transmission.
机译:这篇评论考虑了使用抗逆转录病毒药物专门预防HIV传播。抗逆转录病毒疗法(ART)可以在暴露于HIV感染之前(预防前)和暴露后(预防后)实施,以保护未感染的个体。当个体间歇性接触或连续不断地给那些持续暴露的人服用每日预防剂时,可以独立地使用暴露前预防。暴露后预防用于28天的课程。或者,可以策略性地使用抗逆转录病毒疗法以减少病毒载量和由此感染的艾滋病毒感染者的传染性,从而限制病毒继续传播的风险。已提出一项普遍的艾滋病毒检测政策,以增强对所有艾滋病毒阳性患者的识别,然后立即治疗所有艾滋病毒阳性患者,无论其CD4细胞数如何(普遍检测和治疗),都是能够减少在人口一级的艾滋病毒发病率。这一概念代表了抗病毒治疗使用的范式转变,将传染性个体作为预防对象,而不是保护未感染的暴露人群。该战略的优势在于可以预防传播并降低人群中的艾滋病毒感染率,并为所有艾滋病毒和艾滋病患者提供普遍获得治疗的机会,从而有可能消除母婴艾滋病毒的传播并限制诸如结核。这篇评论批判性地检查了预防艾滋病毒的抗病毒治疗的科学基础,总结了潜在的扩大抗病毒治疗的风险和机会。具体而言,就对病毒传播的影响而言,我们与增强HIV测试和对HIV感染者的治疗相比,考虑了支持和反对针对HIV未感染者的证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号